What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
Peter Johnson mainly focuses on Internal medicine, Lymphoma, Rituximab, Surgery and Follicular lymphoma.
His Internal medicine research includes elements of Gastroenterology and Oncology.
The concepts of his Lymphoma study are interwoven with issues in Germinal center, Cancer research and Radiation therapy.
His work deals with themes such as CHOP, B cell and CD20, which intersect with Rituximab.
His research in Surgery tackles topics such as Tolerability which are related to areas like Standard treatment, Working Formulation and Aggressive lymphoma.
His Follicular lymphoma study incorporates themes from Mutation, B-cell lymphoma, Biopsy and Bone marrow.
His most cited work include:
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma (1020 citations)
- Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study (887 citations)
- European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma (436 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Lymphoma, Oncology, Cancer research and Surgery.
As part of his studies on Internal medicine, he often connects relevant subjects like Gastroenterology.
As part of his Pathology and Immunology and Lymphoma studies, he is studying Lymphoma.
His Oncology study integrates concerns from other disciplines, such as ABVD and Hodgkin lymphoma.
Regimen is the focus of his Surgery research.
His Immunotherapy research integrates issues from Antibody and Monoclonal antibody.
He most often published in these fields:
- Internal medicine (28.08%)
- Lymphoma (15.34%)
- Oncology (14.62%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (28.08%)
- Oncology (14.62%)
- Lymphoma (15.34%)
In recent papers he was focusing on the following fields of study:
Peter Johnson focuses on Internal medicine, Oncology, Lymphoma, Cancer research and Diffuse large B-cell lymphoma.
His studies in Internal medicine integrate themes in fields like Gastroenterology and Surgery.
Peter Johnson combines subjects such as Cancer, Chemotherapy, Hodgkin lymphoma, Proportional hazards model and CD20 with his study of Oncology.
Peter Johnson has included themes like Positron emission tomography and Precision medicine in his Lymphoma study.
His research in Cancer research intersects with topics in Ibrutinib and Chronic lymphocytic leukemia.
Peter Johnson focuses mostly in the field of Diffuse large B-cell lymphoma, narrowing it down to topics relating to Rituximab and, in certain cases, Prednisone and Chlorambucil.
Between 2016 and 2021, his most popular works were:
- Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma (125 citations)
- Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial (101 citations)
- Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study (100 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His main research concerns Internal medicine, Lymphoma, Oncology, Rituximab and Diffuse large B-cell lymphoma.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Surgery.
His Surgery research incorporates themes from Odds ratio and Hazard ratio.
His research investigates the connection between Lymphoma and topics such as Radiation therapy that intersect with issues in Hodgkin lymphoma and Chemotherapy.
His research investigates the connection with Rituximab and areas like Prednisone which intersect with concerns in Cyclophosphamide and Ibrutinib.
The Diffuse large B-cell lymphoma study combines topics in areas such as Bortezomib, Neutropenia and Germinal center, B cell.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
